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ABSTRACT
Background Cardiac resynchronisation therapy (CRT) 
requires intensive, complex and multidisciplinary 
care to maximize the clinical benefit. In current 
practice this is typically a task for highly specialised 
physicians. We report on a novel multidisciplinary, 
standardised CRT care pathway (CRT- CPW). 
Experienced clinicians developed a CPW with simple 
and broadly applicable aids based on clinical evidence 
and identified shortcomings in the current CRT care. 
The resulting CPW was implemented at the Maastricht 
University Medical Center, aiming at a transfer from 
heterogeneous physician- led care to standardized 
nurse- led care.
Methods Two CRT patient cohorts were compared 
in this analysis. The benchmarked usual care cohort 
(2012–2014, 122 patients) was compared with the 
CRT- CPW cohort (2015–2017, 115 patients). The 
primary outcomes were process- related: number of 
physician consultations, nurse consultations, length 
of stay (LOS) at implantation and total hospitalisation 
days during 1- year follow- up, and referral- to- 
treatment time. Clinical outcomes were assessed to 
adress non- inferiority of quality of care.
Results Patients in the CRT- CPW cohort consulted 
nurses and technicians significantly more often 
than patients in the usual care cohort (2.4±1.5 
vs 1.7±2.0, p<0.0001 and 4.3±2.5 vs 3.7±1.5, 
p=0.063, respectively). Patients with CRT- CPW 
consulted physicians significantly less often (1.7±1.4 
vs 2.6±2.1, p<0.001). Referral to treatment time 
was significantly reduced in the CRT- CPW group 
(23.6±18.4 vs 37.0±26.3 days, p=0.002). LOS at 
implantation and total hospitalisation days were 
significantly reduced in the CRT- CPW group (1.1±1.2 
vs 1.5±0.7 days, p<0.0001 and 2.4±4.8 vs 4.8±9.3, 
p<0.0001, respectively). Clinical outcome analyses 
showed no significant difference in 12- month all- 
cause mortality and heart failure hospitalisations.
Conclusion The introduction of a novel CRT- CPW 
resulted in a successful transition of physician- led to 
nurse- led care, with a significantly reduced resource 
use and equal clinical outcomes. Future evaluations will 
focus on impact on outcomes versus costs, to evaluate 
cost- effectiveness of the CRT- CPW.
INTRODUCTION
Cardiac resynchronisation therapy (CRT) is 
one of the most successful heart failure (HF) 
therapies that have emerged over the last few 
decades. Several randomised clinical trials 
have shown that CRT reduces symptoms of 
HF, improves exercise capacity and quality 
of life and reduces hospitalisations and 
mortality.1–4 Clinical guidelines of the Euro-
pean Society of Cardiology and the American 
College of Cardiology Foundation/American 
Heart Association endorse these results and 
recommend utilisation of CRT in selected 
patients with HF.3 5–7
Despite guidelines and experts’ consensus, 
variability in patient selection, implantation 
techniques, in- hospital management and 
follow- up is observed in clinical practice.8–10 
A recent multicentre registry revealed 
significant heterogeneity in both defini-
tion of response and non- response to CRT, 
and consequential optimisation of therapy. 
Overall the rate of suboptimal benefit from 
CRT remained as high as 30%.11 In order to 
overcome suboptimal benefit from CRT, care 
for these patients requires thorough selection 
for treatment, skilled implanting physicians 
and a comprehensive follow- up treatment 
and comorbidity management. Few studies 
have introduced CRT care programmes, 
including resource intensive, specialised 
follow- up, personalised therapy delivery and 
frequent visits of patients after CRT implanta-
tion. These studies generally show a positive 
effect on outcomes.12–14 The extensive and 
comprehensive nature of these optimisation 
programmes however limits the widespread 
implementation in clinical practice.
In general HF care, the transition from 
physician- led to nurse- led care has been 
well accepted, as studies show that nurse- led 
multidisciplinary HF programmes result in 
a reduced risk of HF hospitalisation. These 
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programmes have been broadly adapted in clinical prac-
tice.15–19 Moreover, studies have shown that structured 
aids in HF care programmes can lead to improved adher-
ence to guidelines.14 20 21 These developments in general 
HF care, however, have not been introduced into CRT 
care programmes yet.
The present study describes the development and 
implementation of a CRT care pathway (CRT- CPW), a 
blueprint for CRT care transition from physician- led to 
a standardised, nurse- led care programme, which aims to 
reduce healthcare and patient burden at equal or better 




In 2013 three expert centres (Maastricht University 
Medical Center (MUMC+), the Netherlands; Liverpool 
Heart and Chest Hospital, England; and Rigshospitalet 
Copenhagen, Denmark) took the initiative to collectively 
design a CRT- CPW. Consensus meetings were conducted 
to evaluate and discuss currently available evidence and 
local experiences in patient evaluation and selection, 
device implantation, follow- up care and process- related 
factors. CRT- CPW design was deepened into an opera-
tional CRT- CPW for the MUMC+, detailing actions and 
resources needed, as shown in figure 1. Checklists were 
created to be applied during specific contact moments 
with the patient (online supplemental figures 1-4). 
The final consensus CPW consisted of four important 
elements aiming to maintain or improve quality with 
effective resource use: (1) structured involvement of 
both heart failure and electrophysiological expertise in 
the process steps, (2) transition of tasks from physicians 
to specialised nurses and technicians, (3) ensuring to 
check and control variables contributing to optimal CRT 
care by means of checklists at each process step and (4) 
structured planning of patient visits (including hospitali-
sation for implantation) for each process step, with one- 
stop- shop visits, to reduce unnecessary resource use and 
patient burden (figures 1–3).
Operational CRT-CPW
For patients referred for CRT implantation a weekly multi-
disciplinary meeting with HF cardiologists and electro-
physiologists was set up to assess eligibility. (figures 1–3) 
Baseline parameters possibly affecting patient outcomes 
are checked following the ‘referral review’ checklist 
(online supplemental figures 1–4). In case additional 
workup is needed for a patient, the referring physician is 
contacted and the patient is re- evaluated after completion 
of diagnostic evaluations and/or optimisation of general 
HF therapy. After approval for CRT, the implantation 
is scheduled; a one- stop- shop outpatient visit planned 
for preoperative assessment, including education and 
informed consent of the patient. This consultation is 
conducted by the implanting physician and a dedicated 
nurse, guided by a ‘pre- assessment’ checklist (online 
supplemental figure 2). The operational elements of 
the referral review and pre- assessment are displayed in 
figure 1.
CRT- CPW changes related to implantation procedure 
focused on the structural collection of patient- related 
and implantation- related information, in order to be 
Figure 1 Operational CRT- CPW; referral review and pre- assessment. An overview of the referral review and pre- assessment 
parts of the implemented operational CRT- CPW. Steps a patient goes through in the care pathway are indicated with content 
of the assessments and structured AIDS available for the assessment. CRT, cardiac resynchronisation therapy; CRT- CPW, 
CRT care pathway; HF, heart failure; ICD/PM nurse, implantable cardioverter- defibrillator/pacemaker nurse; QoL questionnaire, 
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Figure 2 Operational CRT- CPW; implantation. An overview of the implantation part of the implemented operational CRT- CPW 
with steps a patient goes through in the care pathway are indicated with content of the assessments and structured AIDS 
available for the assessment. CRT, cardiac resynchronisation therapy; CRT- CPW, CRT care pathway; mo, months. *The pre- 
discharge checklist is available in the online supplemental material.
Figure 3 Operational CRT- CPW; follow- up. An overview of the follow- up part of the implemented operational CRT- CPW with 
steps a patient goes through in the care pathway are indicated with content of the assessments and structured AIDS available 
for the assessment. CRT, cardiac resynchronisation therapy; CRT- CPW, CRT care pathway; HF, heart failure; ICD/PM nurse, 
implantable cardioverter- defibrillator/pacemaker nurse; mo, months; QoL questionnaire, Quality of Life questionnaire. *The 
optimisation checklist is available in the online supplemental material. **The multidisciplinary evaluation is the same as the 
referral review multidisciplinary evaluation.
P
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able to facilitate same- day discharge and availability 
of implantation- related information needed during 
follow- up. Hospital discharge was supported by a ‘pre- 
discharge’ checklist (online supplemental figure 3) 
which is introduced to verify the absence of implantation- 
related complications, medication verification, patient 
education and follow- up management planning. The 
operational CRT- CPW implantation phase is summarised 
in figure 2.
The CRT- CPW follow- up management consists of pre- 
planned visits from hospital discharge onwards, up to 
follow- up consultation at 6 months after implantation 
including echocardiographic evaluation. One- stop- 
shop consultations with pacemakernurse/implantable 
cardioverter- defibrillator nurse and device technician at 
1 to 2 weeks, and thereafter HF nurse and technician at 
2 months and 6 months take place. The CRT- CPW did 
not include structured remote monitoring as an inter-
vention, however this was offered as an option to patients 
in both usual care and CRT- CPW group. The device 
technician checks and if applicable changes device 
programming and reports on device HF diagnostics. The 
dedicated HF nurses act on device information, optimise 
HF medical regimen taking into account comorbidity 
affecting treatment and support the patient with medi-
cation compliance and lifestyle changes. All post implant 
consultations are guided by an ‘optimisation’ check-
list (online supplemental figure 4). Whenever optimal 
conditions are not met, consequent actions are taken. 
In case specialist intervention is considered (eg, atrial 
fibrillation or His ablation), this is discussed in the multi-
disciplinary meeting. At 6 months the one- stop- shop 
consultation includes echocardiographic evaluation, and 
benefit from CRT is assessed accordingly. The CRT- CPW 
thus provides structured optimisation for every patient, 
instead of only those that do not respond to therapy as 
expected (so called ‘non- response’). Whenever a patient 
is thought to have improved too little from CRT, despite 
the structured optimisation, the patient is evaluated in 
the multidisciplinary meeting. The CRT- CPW allows for 
planning extra consultations if needed from a device or 
HF perspective with respective specialists and/or nurses. 
The operational CRT- CPW follow- up phase is displayed 
in figure 3.
CRT-CPW implementation
The CRT- CPW has been implemented at the MUMC+. A 
phased implementation strategy was used to introduce 
the CRT- CPW in functional parts of the care process; 
being the patient referral and pre- assessment, the implan-
tation procedure and finally the follow- up management, 
as different stakeholders are involved in these steps. 
Between January and September 2014 all stakeholders 
were trained on the CRT- CPW, using the checklists 
provided and introducing logistical and IT (information 
technology) support changes to improve planning of 
consultations for the patients.
Patient and public involvement
This research was done without patient and public 
involvement.
Data collection and analysis
The study was performed according to the Declaration 
of Helsinki. Baseline characteristics and process metrics 
from all patients, from 6 months before the device inter-
vention until 1 year after device implant were collected by 
extracting data from the MUMC+ (electronic) Hospital 
Information System. All patients that received care in the 
MUMC+ before and after the intervention, and had an 
elective ‘de novo’ CRT device implantation or upgrade 
to CRT were eligible for the study. Patients treated before 
the implementation of the CRT- CPW (January 2012 up 
to December 2014; usual care) were compared with 
patients treated after the implementation of the CRT- 
CPW (January 2015 up to December 2017).
Study outcomes
Process Key Performance Indicators were used as primary 
outcome measures. Process metrics were calculated for 
the period of 6 months prior to implantation of the CRT 
device, up to 12 months after the implantation of the 
CRT device.
Successful transition of care was measured by the 
number of physician and nurse and/or technician 
consultations, with specification of the specialism of the 
physician consulted. Resource utilisation was evaluated 
by number of consultations and number of outpatient 
visits (defined as consultations that are not on the same 
day). Moreover time from referral to CRT device implan-
tation, the length of stay (LOS) in days after implantation 
and the total hospitalisation days during follow- up were 
evaluated.
Even though clinical outcome was not the primary 
focus of the current analyses we have used 12- month all- 
cause mortality and HF hospitalisations as a secondary 
outcome, to address the non- inferiority of quality of care.
Statistical analysis
Results are reported with means and SD for numeric varia-
bles and counts and percentages for categorical variables. 
Variables are compared using Student’s t- test or Wilcoxon 
rank- sum test for continuous variables, Fisher’s exact test 
for proportions, and the Cochran- Mantel- Haenszel test 




In total 837 patients received a CRT device between 
January 2012 and December 2017 at the MUMC+. Of 
these patients, 531 were referred by external physicians, 
with incomplete follow- up data available for analysis. 
Sixty- one patients were non- elective implants, and hence 
data on pre- implantation care was missing. Additionally, 
eight patients were excluded because of missing data on 
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the primary outcomes. The study cohort comprised a 
total of 237 patients available for analysis.
Data collected from 122 patients referred for elective 
implantation of a CRT device according to usual care and 
data from 115 patients after introduction of the CRT- CPW 
were analysed. The baseline characteristics of the two 
cohorts were largely comparable (table 1, Baseline char-
acteristics). CRT- CPW Patients more frequently under-
went an upgrade procedure (23.5 vs 12.3%, p=0.027) and 
more frequently had a history of myocardial infarction 
(47.8 vs 33.6%, p=0.034).
Process metrics
Table 2 (Process metrics) summarises the process metrics 
for the usual care and CRT- CPW. Patients referred for 
a CRT device after CRT- CPW implementation had a 
comparable number of hospital visits to patients with 
usual care (10.1±4.3 vs 10.8±4.1, p=0.21). However, 
there were significantly more pre- implantation visits 
in the CRT- CPW cohort, than in the usual care cohort 
(1.6±1.4 vs 1.2±1.5, p=0.010). CRT- CPW visits included 
significantly more individual consultations than in the 
usual care cohort (9.9±4.2 vs 8.1±3.3, p<0.001). The 
number of consultations were significantly higher in the 
pre- implantation phase (2.1±1.8 vs 1.2±1.5, p<0.0001), 
and showed a trend toward significant increase in the 
post- implantation phase (7.8±3.7 vs 6.9±2.8, p=0.059) 
(table 2).
Patients in the CRT- CPW consulted HF nurses, pace-
maker/ICD nurses and pacemaker/ICD technicians 
significantly more often than patients in the usual care 
cohort (2.4±1.5 vs 1.7±2.0, p<0.0001, 0.8±0.7 vs 0.0±0.3, 
p<0.0001 and 4.3±2.5 vs 3.7±1.5, p=0.063, respectively). 
At the same time patients with CRT- CPW consulted physi-
cians significantly less often (1.7±1.4 vs 2.6±2.1, p<0.001) 
(table 2).
Time from referral to implantation of the CRT device 
was significantly reduced in the CRT- CPW cohort 
(23.6±18.4 vs 37.0±26.3 days, p=0.002). Total hospital-
isation days during the observation period was signifi-
cantly reduced in the patient group with CPW (2.4±4.8 
vs 4.8±9.3, p<0.0001). This reduction includes a signifi-
cant reduction in LOS at implantation (1.1±1.2 vs 1.5±0.7 
days, p<0.0001), with a significant increase in patients 
with a same- day discharge and with only one night stay at 






Male 90 (73.8%) 81 (70.4%) 0.66
Age (years) 0.16
  18–64 35 (28.7%) 24 (20.9%)
  65–74 43 (35.2%) 45 (39.1%)
  75–99 44 (36.1%) 46 (40.0%)
NYHA class 0.071
  Class I 5 (4.1%) 6 (5.2%)
  Class II 70 (57.4%) 46 (40.0%)
  Class III 25 (20.5%) 29 (25.2%)
  Class IV 1 (0.8%) 5 (4.3%)
  Missing 21 (17.2%) 29 (25.2%)
  LBBB 61 (50.0%) 59 (51.3%) 0.90
  QRS duration (ms) 161.5±29.1 159.7±29.2 0.62
  LVEF (%) 29.4±8.4 30.2±8.8 0.50
  Ischaemic cardiomyopathy 52 (42.6%) 59 (51.3%) 0.19
  Hypertension 48 (39.3%) 41 (35.7%) 0.59
  Myocardial infarction 41 (33.6%) 55 (47.8%) 0.034
  Atrial fibrillation 49 (40.2%) 57 (49.6%) 0.15
  Chronic lung disease 18 (14.8%) 14 (12.2%) 0.58
  Diabetes 21 (17.2%) 32 (27.8%) 0.061
  Glomerular filtration rate (MDRD formula) 62.2±27.5 59.4±21.1 0.38
  Beta blocker 103 (84.4%) 98 (85.2%) 1.00
  ACEi / ARB 106 (86.9%) 99 (86.1%) 1.00
  MRA 56 (45.9%) 68 (59.1%) 0.051
  Upgrade 15 (12.3%) 27 (23.5%) 0.027
  ICD 90 (73.8%) 79 (68.7%) 0.39
*P- value comparesusual care and the CRT- CPW. Tests used are Student t- test,Cochran- Mantel- Haenszel test, Fisher exact test. P- value<0.05 is considered significant
ACEi, angiotensin- converting enzyme- inhibitor; ARB, angiotensin II- receptor blocker; CRT, cardiac resynchronisation therapy; CRT- CPW, CRT care pathway; ICD, implantable 
cardioverter- defibrillator; LBBB, left bundle branch block; LVEF, left ventricular ejection fraction; MRA, mineralocorticoid receptor antagonist; NYHA, New York Heart Association.
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implantation (28 vs 7% and 78 vs 43%, respectively, both 
p<0.0001) (table 2).
Clinical outcomes
Table 3 (Clinical outcomes) summarises the clinical 
outcomes for the usual care and CRT- CPW at 12 months 
follow- up. Patients referred for a CRT device after CRT- 
CPW implementation were hospitalised for HF less 
often than patients referred for a CRT device before its 
implementation (5.2% vs 9.0%, p=0.32). Also patients 
12- month mortality was (non- significantly) lower when 
patients were implanted with a CRT device after CRT- 
CPW implementation (3.5% vs 6.6%, p=0.38) (table 3).
DISCUSSION
Implementing a CRT- CPW using multidisciplinary care, 
in a structured, checklist driven patient management 
protocol resulted in a successful transition of physi-
cian- led usual care to nurse- led CRT patient management. 
Moreover it led to a significant reduction in resource use; 
with a reduction in hospitalisation days and physician 
consultations. These changes did not lead to inferior clin-
ical outcomes, as mortality and HF hospitalisation at 12 
months were non- inferior to usual care.
Mullens et al were the first to show that the use of a stan-
dardised algorithm in patients that did not derive benefit 
from CRT could identify factors associated with subop-
timal treatment, and if corrected this was associated with 
improved clinical outcome.14 Importantly, these favour-
able effects appeared to be driven not only by appropriate 
device and arrhythmia management but also by improved 
HF care.22 These results were recently strengthened by 
another study comparing multidisciplinary, comprehen-
sive CRT care to conventional CRT care.12 A communal 
factor in the programmes evaluated in these studies 
however, is that they require intensive, specialised, physi-
cian guided follow- up, with extensive resource use, which 
hampers widespread adoption in clinical practice.
The CRT- CPW as applied at the MUMC+ shared the 
aim to improve quality of care for patients with CRT by 
applying multidisciplinary expertise, in a structured way 
in order to identify any opportunity for optimisation of 
treatment at any moment in the care process. But at the 
same time, the current CPW aimed to establish a transi-
tion of care from highly specialised (physicians- led) care 
to protocolled, nurse- led care, with structured planning 
of patient visits to establish a reduction in resource use.
Table 2 Process metrics
Process metrics
Usual care (n=122) CRT- CPW (n=115)
P value*Mean±SD Median (IQR) Mean±SD Median (IQR)
Outpatient clinic visits (n) 10.8±4.1 10.0 (8–13) 10.1±4.3 10.0 (7–12) 0.21
  Pre procedure 1.2±1.5 1.0 (0–2) 1.6±1.4 1.0 (0–2) 0.010
  Post procedure 6.8±2.7 7.0 (5–8) 7.5±3.5 7.0 (5–10) 0.099
Outpatient clinic consultations (n) 8.1±3.3 8.0 (6–10) 9.9±4.2 10.0 (7–12) <0.001
  Pre procedure 1.2±1.5 1.0 (0–2) 2.1±1.8 2.0 (0–3) <0.0001
  Post procedure 6.9±2.8 7.0 (5–8) 7.8±3.7 7.0 (5–10) 0.059
  Physician 2.6±2.1 2.0 (1–4) 1.7±1.4 2.0 (1–2) <0.001
  HF nurse 1.7±2.0 1.0 (0–3) 2.4±1.5 2.0 (1–3) <0.0001
  Pacemaker/ICD nurse 0.0±0.3 0.0 (0–0) 0.8±0.7 1.0 (0–1) <0.0001
  Pacemaker/ICD technician 3.7±1.5 3.0 (3–4) 4.3±2.5 4.0 (3–5) 0.063
  Time to treatment 37.0±26.3 29.2 (16–53) 23.6±18.4 21.0 (10–31) 0.002
  Length of hospital stay (days) 4.8±9.3 2.0 (1–2) 2.4±4.8 1.0 (1–2) <0.0001
  Post procedure (implant to discharge) 1.5±0.7 2.0 (1–2) 1.1±1.2 1.0 (0–1) <0.0001
  Same- day discharge (%) 7% 28% <0.0001
  ≤1 night stay (%) 43% 78% <0.0001
  Follow- up (discharge to 1 year) 3.2±9.2 0.0 (0–0) 1.3±4.6 0.0 (0–0) 0.27
*P- value compares old and new pathways. Tests used are Wilcoxon ranksumand Fisher exact tests. P- value<0.05 is considered significant
CRT, cardiac resynchronisation therapy; CRT- CPW, CRT care pathway; HF, heart failure; ICD, implantable cardioverter- defibrillator.
Table 3 Clinical outcomes





Death within 12 
months from 
procedure
8 (6.6%) 4 (3.5%) 0.38
Admitted for HF 
within 12 months 
from procedure
11 (9.0%) 6 (5.2%) 0.32
Number of 
admissions
  1 7 6
  2 3 0
  3 1 0
*P- value compares old and new pathways. Tests used is the Fisher 
exact test. P- value<0.05 is considered significant
CRT, cardiac resynchronisation therapy; CRT- CPW, CRT care 
pathway; HF, heart failure.
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The current study showed that a transition was made 
from physician- based care to the nurse- led program. Non- 
dedicated physician- led care, incorporating different kind 
of specialised cardiologists was transferred to the CRT- 
CPW nurse- led care. The evaluation showed that there 
still were physician contributions to the HF care in the 
patient with CRT- CPW group. This may be explained by 
destabilised HF which demanded physician consultation, 
specialised consultation in order to target factors contrib-
uting to suboptimal treatment or simply incomplete 
implementation of the CRT- CPW. In addition, implemen-
tation of the new CRT- CPW may have been incomplete as 
simultaneous and complete training of all contributors to 
CRT care before the start of the practical use of the CRT- 
CPW was not possible. As implementation of new CPWs 
expands over time, especially when contributors see the 
added value of it, we expect the number of physician 
consultations to decrease further over time. However, 
as specialised interventions (eg, atrial fibrillation or His 
ablation procedures) may be required in structured opti-
misation, physician consultations will remain at a minimal 
level needed to reassure optimal CRT care.
Even though we successfully transferred care for these 
patients to dedicated CRT and HF nurses and techni-
cians, the number of visits was not significantly lower in 
the CRT- CPW cohort. Due to the uncoordinated care in 
the usual care cohort, we expected this to be lower in 
the CRT- CPW group. Our data shows that the introduc-
tion of the one- stop- shop visits in the CRT- CPW resulted 
in a reduced need for repetitive visits, as the overall 
number of consultations significantly increased in the 
CRT- CPW, but patient visits to the outpatient clinic were 
not different. This is possible as the pathway allowed for 
deviations when either optimisation or stabilisation of HF 
required this. One explanation may therefore be that in 
the checklist driven CRT- CPW more possibilities for opti-
misation were identified, requiring extra consultations, 
for example, optimisation of HF medication, treatment 
of congestion or device reprogramming. Another expla-
nation may be an increase in destabilised HF, however if 
the excess consultation would have been the result of this, 
we would expect to have seen a coinciding increase in HF 
hospitalisations and overall hospitalisation days during 
follow- up. Other studies introducing structured check-
list into general HF care have shown that restructuring 
HF care, aided by checklists helped to improve guideline 
adherence for the outpatient and admitted HF popu-
lation, respectively,20 21 therefore we believe that future 
evaluations will reflect this in improved patient outcomes.
Another result of the enhanced coordination and plan-
ning by the multidisciplinary team is the reduced time 
between referral and device implantation, with more 
than 35% reduction. Shorter time to any intervention 
generally contributes greatly to patient satisfaction with 
their medical treatment.23 Moreover, in patients with 
HF, timely intervention may prevent hospitalisation due 
to destabilised HF. With the use of a ‘referral’ review 
and ‘pre- assessment’ checklists incomplete diagnostic 
work- up or lack of general HF optimisation can be identi-
fied at referral and managed in a coordinated way. More-
over, the reduction in device- implantation related LOS 
was possible due to (1) discussion of and consent to a 
discharge plan with the patient at the pre- implantation 
one- stop- shop meeting, and (2) the introduction of a 
discharge checklist, available to the ward nurse to reas-
sure absence of any complications, enabling an early 
discharge.
Finally, the current evaluation showed a non- significant 
decrease in all- cause mortality and HF hospitalisation. 
Even though this was not the primary aim of the current 
evaluation, these results express the non- inferiority of 
the nurse- led, checklist- guided, CRT- CPW compared 
with usual care with respect to clinical outcomes. As the 
selected cohort of patients analysed in the current paper 
specifically fits the primary aim of process evaluation it 
does not allow to show superiority on clinical outcomes. 
Reduced mortality and HF hospitalisations (even though 
non- significantly) may point to an improved clinical 
outcome, as reduction of HF hospitalisation is one of 
the main targets in HF management. Moreover, hospital-
isations remain the largest expense in HF care,24 and a 
reduction may lead to a significant reduction in health-
care costs. Efforts are currently being made to evaluate 
relevant medical outcomes and costs, in order to report 
on cost- effectivity of the CRT- CPW.
Strengths and future: This CRT- CPW allows for adjust-
ments to local practices and hospital care teams, while still 
providing quality care for patients with CRT by making use 
of standardised forms and algorithms. Further improve-
ment of data collection by automatic data entry into the 
hospital information system combined with integration of 
the CRT- CPW into standard medical practice will provide 
a unique opportunity to standardise and continuously 
evaluate patient care. This potential may lead to contin-
uous improvement of quality of care, resource use and 
innovation in CRT care.
Limitations: This study uses a historical control to 
evaluate the CRT- CPW effect on process metrics, this 
introduces a possible bias. Other influences on process 
outcomes may have been introduced over time, affecting 
the results. Furthermore, even though the pathway 
aims to be simple and adoptable to any clinical prac-
tice, it is uncertain whether the presented results will 
be similar in other centres. Other hospitals have started 
to implement the CRT- CPW, which provides opportuni-
ties for future evaluations. A limited number of patients 
were included in both cohorts, patients referred from 
other hospitals and hospitalised patients were excluded 
because of incomplete follow- up. Next to patient clinical 
outcomes, patient satisfaction with the care pathway have 
not been addressed in the current paper. However it may 
be expected that patients appreciate the reduced time 
to treatment, improved communication between stake-
holders and the efficient care team interaction.
P
rotected by copyright.
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Open access 
CONCLUSION
The introduction of a CRT- CPW using a protocolled, 
multidisciplinary approach with structured aids, led to 
a successful transition of physician- led care to nurse- led 
care, with a significant reduction in hospital resource use, 
and non- inferior clinical outcomes, compared with usual 
care.
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